



## NOTICE OF MEETING

### NOXOPHARM 2016 AGM Sydney Briefing

**November 25, 2016 at 4pm**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

Following the Company's AGM in Melbourne on November 23, 2016, Noxopharm Limited (ASX: NOX) will be holding an AGM Sydney Briefing on November 25<sup>th</sup> at 4pm at the Grace Hotel, 77 York Street, Sydney.

Attendees will have the opportunity to meet with the Noxopharm Board of Directors.

CEO, Dr Graham Kelly, also will review the Company's clinical trial programme and general drug development strategy.

Please RSVP for this event to: Prue Kelly [info@noxopharm.com](mailto:info@noxopharm.com) or call Noxopharm + 61 2 91442223

#### About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.